Search bioRxiv⌕ Search

Biology subjects

Ranasinghe, D.

Publications and source records attributed to Ranasinghe, D..

2 recordsLinked to original sources

Blind Virtual Screening at Scale: A Scalable End-to-End Pipeline for Blind Docking and Affinity Prediction

Accurate and scalable prediction of protein-ligand interactions remains a central challenge in computational drug discovery, especially when the binding site is unknown (i.e., blind docking). We present a high-throughput, end-to-end algorithm for virtual screening that combines DiffDock, a diffusion-based generative model for blind docking, with UniDock Vina, an algorithm for rapid scoring. We benchmarked this approach on the CASF-2016 and DUD-E datasets, analyzing pose quality, scoring accuracy, and screening performance. We find that competitive screening power can be achieved when generating and scoring as few as three poses and without pose refinement, which facilitates scalability. Notably, our method achieves 86.78% and 82.00% for the percent of actives among the top 1% and 10% of ranked ligands, respectively, when generating as few as three poses per protein-ligand pair. The workflow is scalable, supporting blind docking and affinity prediction at a mean throughput of 0.76 seconds per protein-ligand pair when generating 40 ligand poses in batched mode parallelized to 8 NVIDIA A100 80G GPUs. These results demonstrate that accurate, large-scale blind virtual screening is feasible and offers a practical solution for screening against novel or less characterized protein targets. Code is available at: https://github.com/xinyu-dev/blind-screening-benchmark

bioinformatics↗

Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation

Somatic mutations that increase hematopoietic stem cell (HSC) fitness drive their expansion in clonal hematopoiesis (CH) and predispose to blood cancers. Although CH frequently occurs with aging, it rarely progresses to overt malignancy. Population variation in the growth rate and potential of mutant clones suggests the presence of genetic factors protecting against CH, but these remain largely undefined. Here, we identify a non-coding regulatory variant, rs17834140-T, that significantly protects against CH and myeloid malignancies by downregulating HSC-selective expression and function of the RNA-binding protein MSI2. By modeling variant effects and mapping MSI2 binding targets, we uncover an RNA network that maintains human HSCs and influences CH risk. Importantly, rs17834140-T is associated with slower CH expansion rates in humans, and stem cell MSI2 levels modify ASXL1-mutant HSC clonal dominance in experimental models. These findings leverage natural resilience to highlight a key role for post-transcriptional regulation in human HSCs, and offer genetic evidence supporting inhibition of MSI2 or its downstream targets as rational strategies for blood cancer prevention.

genetics↗